等待开盘 10-21 09:30:00 美东时间
+5.620
+3.15%
The US FDA has accepted Replimune's (NASDAQ:REPL) BLA submission of RP1 in combination with Bristol Myers Squibb's (BMY) Opdivo (nivolumab) for advanced melanoma. Shares are up ~108% in pre-market tra...
10-20 21:00
今日重点评级关注:韦德布什:维持Artiva Biotherapeutics"跑赢大市"评级,目标价从18美元升至23美元;巴克莱:维持Cellectis"超配"评级,目标价从4美元升至8美元
10-20 10:03
Xbrane Biopharma AB ( ($SE:XBRANE) ) has issued an announcement. Xbrane Biophar...
10-20 02:32
Mizuho analyst Ann Hynes maintains Charles River (NYSE:CRL) with a Neutral and raises the price target from $155 to $174.
10-17 21:17
美国货币监理署(OCC)近期政策变动推动 Circle、Ripple、Paxos、Coinbase 等多家加密货币公司申请国家信托银行牌照。这些企业寻求通过该牌照扩大业务范围,提升合规性。Paxos 和 Anchorage Digital 已获初步批准,Anchorage 成为美国首家数字资产银行。Circle 设立 First National Digital Currency Bank,Paxos 和 Coinbase 则分别计划提供托管服务和支付解决方案。Bridge 由 Stripe 收购后也加入申请行列。申请潮主要源于美国《GENIUS法案》激励,企业合规扩张需求及提升形象推动行业发展。
10-15 07:52
Rocket Pharmaceuticals (NASDAQ:RCKT) added ~11% in the premarket on Tuesday after the company announced that the FDA had accepted its resubmitted marketing application for its gene therapy candidate K...
10-14 20:21
Scholar Rock stock falls as FDA issues Form 483 to Catalent; company to meet FDA, while apitegromab shows lean mass preservation in trial.
10-14 01:52
Adhishthana.com notes Charles River Stock is nearing its Phase 18, with momentum weakening and long-term outperformance looking unlikely.
10-07 19:22
今日重点评级关注:Ascendiant Capital:维持Society Pass"买入"评级,目标价从15美元升至18美元;Ascendiant Capital:维持Surgepays"买入"评级,目标价从9美元升至9.5美元
10-06 08:35
稳定币虽看似简单,实则为高利润的“重”生意。Tether等发行商通过高额利差实现显著收益,但其商业模式高度依赖美联储政策。9月降息已使行业面临5亿美元收入损失。同时,合规成本高昂,初创企业难以承担。面对挑战,Tether推出Plasma公链,Circle则开发新支付网络,寻求更多收入来源。稳定币赛道竞争激烈,唯有深谙本质且迅速行动的企业,方能在市场动荡中存活。
10-06 03:55